RAPT THERAPEUTICS, INC.
561 Eccles Avenue
South San Francisco, California 94080
November 10, 2020
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
RAPT Therapeutics, Inc.
Registration Statement on Form S-3
Filed November 4, 2020
File No. 333-249848
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the Registrant) hereby requests that the Securities and Exchange Commission (the Commission) take appropriate action to cause the Registration Statement on Form S-3 (File No. 333-249848) (the Registration Statement) to become effective on Monday, November 16, 2020, at 9:00 a.m., Eastern Time, or as soon as practicable thereafter, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission (the Staff). The Registrant hereby authorizes each of Michael Tenta and Ryan James of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Ryan James of Cooley LLP, counsel to the Registrant, at (650) 843-5846, or, in his absence, Michael Tenta of Cooley LLP at (650) 843-5636.
In connection with this request, the Registrant acknowledges that:
should the Commission or the Staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
the Registrant may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
|RAPT THERAPEUTICS, INC.|
|Title:||Chief Financial Officer|
Michael Tenta, Cooley LLP
Ryan James, Cooley LLP